Hepatic artery chemotherapy was given to 36 patients, using totally implantable devices consisting of a port and external pump. Twenty-seven patients had inoperable liver metastases ofcolorectal origin. The infusion system was inserted by laparotomy into the hepatic artery via the gastroduodenal artery. There was no operative mortality. Thirteen infusion systems could not be used for chemotherapy due to dislodgement, early death and lack of follow-up. FUdR was infused every two weeks. There were minor local complications like thrombosis of the system and dislodgement of the port. 
INTRODUCTION:
80% of patients who succumb from colorectal cancer die of hepatic metastases .S o far hepatic resection has been the only curative intervention: The five year survival rate is 25% 2 and 330/03 Nevertheless, the chances of curative resection are no higher than 8% 4 To help in the incurable state ofinoperable liver metastases, palliative methods have been developed: 1 . Systemic chemotherapy with a maximum response of 20%5'6.
2. Regional hepatic chemotherapy has been introduced, presupposing that perfusion of the liver metastases is predominantly by the hepatic artery7'8. Regional hepatic artery chemotherapy was first performed via percutaneous angiography catheters9'. However, external catheter-related complications, such as dislodgement, infection or thrombosis were limiting factors with this procedure. Since totally implantable devices 11 12 with port or pump have been introduced this method has become widely accepted. Response to chemotherapy was evaluated six months after initiation, checking survival, clinical condition, CEA levels, ultrasound and CT (Table 2 ). Ten/twentythree (43%) of our patients were considered responders. Nine of these responders belong to the colorectal group, one had liver metastases due to uterine carcinoma. Six were non-responders ( Table 2) . Four of these patients had a colorectal primary carcinoma, one choroid membrane carcinoma and one a hepatoma. Disease was assessed as stable in seven patients ( Table 2 ). Five of these had metastases due to colorectal cancer, one due to breast cancer and one due to hepatoma. Six/ten responders showed a marked decrease of CEA levels from 343(6-1200) ng/ml before hepatic chemotherapy to 53(3.2-100.8) ng/ml at six months (Table 2) . Three/ten patients had a complete remission by ultrasound, 4/10 by CT (Figures and 2) .
Nevertheless, five out of ten developed extrahepatic metastases although they had responded to therapy at six months: four had lung metastases and one had brain metastasis. The goals of regional chemotherapy are to maximize concentration of chemotherapeutic drugs. The superiority of hepatic artery chemotherapy compared to the portal vein route was reported in a controlled study24. 15%. The disease-free interval was seven and nine months respectively. The goal to be achieved with hepatic artery infusion chemotherapy should be: 1. a less toxic cytostatic agent in order to avoid complications to the bile ducts, the stomach, the duodenum and the pancreas, 2. a combination with systemic chemotherapy to avoid extra-hepatic metastases and 3. a combination with surgery, yielding inoperable metastases operable by regional chemotherapy prior to liver resection.
INVITED COMMENTARY
The advent of the technology for hepatic artery infusion using an implantable system with a port has certainly contributed to the management of patients with advanced metastatic diseases of the liver and a considerable number of papers have been published. However, a high incidence rate of complications such as dislodgement of clogging of the catheter, infection around the port, mis-directed perfusion and side effects of anti-tumor agents is a serious problem inherent to this technique. In fact, it is an unacceptable problem, if chemotherapy has to be discontinued because of these complications, especially in the patients in whom the catheter was surgically inserted into the hepatic artery.
In our Department, one-shot transcatheter infusion of an anti-tumor agent suspended in oil (Nimustine-Lipiodol suspension) has been indicated as the method of choice in these cases for the last 3 years and a favorable result has been obtained. Nimustine, a derivative of Nimustine hydrochloride, was suspended in Lipiodol using ultrasonic agitation and used in experimental animals and human subjects. In 2 out of 5 cases with hepatoma which responded to treatment, hepatic lobectomy was carried out some days later. In these cases, although a tiny cancerous lesion was histologically detected at the edge in the subcapsular region a surrounding cystic lesion replaced the tumor, an obvious effect of this agent. In the remainder, administration of anti-tumor agent has been repeated at various intervals when tumor-markers become re-elevated.
Our previous experimental study found that the anti-tumor agent suspended in Lipiodol is gnore selectively accumulated and more slowly released in tumor tissue, resulting in a long-acting effect, compared with that of an anti-tumor agent such as FUdR dissolved in water. Moreover, another advantage to using Lipiodol is that information necessary for follow-up studies can be easily obtained, because the lesion is clearly delineated with Lipiodol.
The patients in which this type of treatment is indicated are, in general, in a grave condition. Therefore, the type of anti-tumor agent and method of its administration should be seriously considered before it is given.
